NASDAQ:ALIMAlimera Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alimera Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.36 +0.23 (+4.48 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$5.24Now: $5.36▼$5.4050-Day Range$3.44MA: $4.92▼$5.8152-Week Range$2.86Now: $5.36▼$15.45Volume2,108 shsAverage Volume15,423 shsMarket Capitalization$26.96 millionP/E RatioN/ADividend YieldN/ABeta2.25 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.67, Alimera Sciences has a potential upside of 360.2% from its current price of $5.36.Amount of Analyst CoverageAlimera Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAlimera Sciences has received 327 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlimera Sciences has received 323 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlimera Sciences has received 50.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote “Outperform” if you believe ALIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.60% of the stock of Alimera Sciences is held by insiders.Percentage Held by InstitutionsOnly 23.21% of the stock of Alimera Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow in the coming year, from ($2.42) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALIM Previous Symbol CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone678-990-5740Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio3.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$53.94 million Price / Sales0.50 Cash FlowN/A Price / Cash FlowN/A Book Value($7.01) per share Price / Book-0.76Profitability EPS (Most Recent Fiscal Year)($2.19) Net Income$-10,440,000.00 Net Margins-15.97% Return on EquityN/A Return on Assets-18.09%Miscellaneous Employees124 Outstanding Shares5,030,000Market Cap$26.96 million Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:ALIM Rates by TradingView Receive ALIM News and Ratings via Email Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter. Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions How has Alimera Sciences' stock been impacted by COVID-19 (Coronavirus)? Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALIM shares have increased by 2.3% and is now trading at $5.36. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Alimera Sciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alimera Sciences. When is Alimera Sciences' next earnings date? Alimera Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Alimera Sciences. How were Alimera Sciences' earnings last quarter? Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings data on Wednesday, April, 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.19. The biopharmaceutical company had revenue of $14.54 million for the quarter, compared to analyst estimates of $14.04 million. View Alimera Sciences' earnings history. When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work? Shares of Alimera Sciences reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split. What guidance has Alimera Sciences issued on next quarter's earnings? Alimera Sciences updated its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14 million, compared to the consensus revenue estimate of $12.87 million. What price target have analysts set for ALIM? 3 brokerages have issued 1-year price objectives for Alimera Sciences' stock. Their forecasts range from $14.00 to $45.00. On average, they expect Alimera Sciences' stock price to reach $24.67 in the next twelve months. This suggests a possible upside of 360.2% from the stock's current price. View analysts' price targets for Alimera Sciences. Has Alimera Sciences been receiving favorable news coverage? News coverage about ALIM stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alimera Sciences earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAlimera Sciences. Are investors shorting Alimera Sciences? Alimera Sciences saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,500 shares, a decline of 37.5% from the April 30th total of 4,000 shares. Based on an average daily volume of 32,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the company's stock are sold short. View Alimera Sciences' Current Options Chain. Who are some of Alimera Sciences' key competitors? Some companies that are related to Alimera Sciences include ESSA Pharma (EPIX), Eton Pharmaceuticals (ETON), Oncolytics Biotech (ONCY), CV Sciences (CVSI), Aptorum Group (APM), Catalyst Biosciences (CBIO), Bellerophon Therapeutics (BLPH), TFF Pharmaceuticals (TFFP), Genprex (GNPX), Sesen Bio (SESN), Clearside Biomedical (CLSD), Celsion (CLSN), Proteostasis Therapeutics (PTI), ContraFect (CFRX) and Milestone Pharmaceuticals (MIST). View all competitors. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), Agenus (AGEN), Opko Health (OPK), Advanced Micro Devices (AMD), Catalyst Pharmaceuticals (CPRX), CorMedix (CRMD) and Novavax (NVAX). Who are Alimera Sciences' key executives? Alimera Sciences' management team includes the following people: Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)Dr. Kenneth Green, Consultant (Age 61)Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)Mr. J. Philip Jones, Chief Financial Officer (Age 55) What is Alimera Sciences' stock symbol? Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM." How do I buy shares of Alimera Sciences? Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Alimera Sciences' stock price today? One share of ALIM stock can currently be purchased for approximately $5.36. How big of a company is Alimera Sciences? Alimera Sciences has a market capitalization of $26.96 million and generates $53.94 million in revenue each year. The biopharmaceutical company earns $-10,440,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe. What is Alimera Sciences' official website? The official website for Alimera Sciences is www.alimerasciences.com. How can I contact Alimera Sciences? Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
